Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
TK Kim, EN Vandsemb, RS Herbst… - Nature Reviews Drug …, 2022 - nature.com
Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …
Resistance mechanisms to anti-PD cancer immunotherapy
The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …
Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis
Importance PD-L1 (programmed cell death ligand 1) immunohistochemistry (IHC), tumor
mutational burden (TMB), gene expression profiling (GEP), and multiplex …
mutational burden (TMB), gene expression profiling (GEP), and multiplex …
Human-interpretable image features derived from densely mapped cancer pathology slides predict diverse molecular phenotypes
Computational methods have made substantial progress in improving the accuracy and
throughput of pathology workflows for diagnostic, prognostic, and genomic prediction. Still …
throughput of pathology workflows for diagnostic, prognostic, and genomic prediction. Still …
[HTML][HTML] A snapshot of the PD-1/PD-L1 pathway
Cancer cells can evade the attack from host immune systems via hijacking the regulatory
circuits mediated by immune checkpoints. Therefore, reactivating the antitumor immunity by …
circuits mediated by immune checkpoints. Therefore, reactivating the antitumor immunity by …
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
With recent approvals for multiple therapeutic antibodies that block cytotoxic T lymphocyte
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma …
associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) in melanoma …
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Gloss PD-L1 and PD-1 (PD) pathway blockade is a highly promising therapy and has
elicited durable antitumor responses and long-term remissions in a subset of patients with a …
elicited durable antitumor responses and long-term remissions in a subset of patients with a …
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Extracellular interaction between programmed death ligand-1 (PD-L1) and programmed cell
death protein-1 (PD-1) leads to tumour-associated immune escape. Here we show that the …
death protein-1 (PD-1) leads to tumour-associated immune escape. Here we show that the …
A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung cancer
Importance Four assays registered with the US Food and Drug Administration (FDA) detect
programmed cell death ligand 1 (PD-L1) to enrich for patient response to anti–programmed …
programmed cell death ligand 1 (PD-L1) to enrich for patient response to anti–programmed …
Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer
J Brahmer, KL Reckamp, P Baas, L Crinò… - … England Journal of …, 2015 - Mass Medical Soc
Background Patients with advanced squamous-cell non–small-cell lung cancer (NSCLC)
who have disease progression during or after first-line chemotherapy have limited treatment …
who have disease progression during or after first-line chemotherapy have limited treatment …